INTENSITY THERAPEUTICS, INC.
A late-stage clinical company developing intratumoral therapies for solid tumors.
INTS | US
Overview
Corporate Details
- ISIN(s):
- US45828J1034
- LEI:
- Country:
- United States of America
- Address:
- 1 ENTERPRISE DRIVE, SUITE 430, 6484 SHELTON
- Sector:
- Manufacturing
Description
Intensity Therapeutics, Inc. is a late-stage clinical company developing a novel intratumoral approach to treat solid tumor cancers. Its proprietary DfuseRx℠ platform technology facilitates the direct injection of therapeutic agents into tumors, enabling high drug absorption and dispersion. This "treat locally, act globally" method is designed to kill cancer cells in the injected tumor and simultaneously stimulate a systemic, personalized T-cell immune response against both the primary tumor and distant metastases. The company's lead product candidate, INT230-6, is advancing in late-stage clinical trials for multiple cancers, including sarcoma and breast cancer. The goal is to extend survival for patients with metastatic disease and prevent recurrence in presurgical settings.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all INTENSITY THERAPEUTICS, INC. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for INTENSITY THERAPEUTICS, INC.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for INTENSITY THERAPEUTICS, INC. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
